Product Description
Pazopanib is a cancer medicine that is used to treat patients with kidney cancer (advanced renal cell carcinoma). It is also used to treat advanced soft tissue sarcoma (STS) in patients who have received other cancer treatments.
AI Product Description
*The following content is generated by AI and is for reference only.
Pazopanib Hydrochloride is a potent, orally available small-molecule tyrosine kinase inhibitor (TKI) widely recognized in the field of oncology for its ability to target multiple receptor tyrosine kinases. With the Chemical Abstracts Service (CAS) number 649210-58-6, this compound serves as the hydrochloride salt form of pazopanib, enhancing its solubility and stability for pharmaceutical formulation. Its molecular formula is C₂₁H₂₆ClN₅O₃S, reflecting a complex structure designed to inhibit angiogenesis and tumor growth by blocking key signaling pathways.
Primarily used as an active pharmaceutical ingredient (API), Pazopanib Hydrochloride is indicated for the treatment of advanced renal cell carcinoma (RCC), soft tissue sarcoma, and hepatocellular carcinoma in specific clinical settings. The drug functions by inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and stem cell factor receptor c-KIT. By suppressing these receptors, it effectively disrupts the blood supply to tumors, thereby starving cancer cells of nutrients and oxygen required for proliferation and metastasis. This multi-targeted approach distinguishes it from single-agent inhibitors and offers broad-spectrum efficacy against various solid tumors.
In the global pharmaceutical market, Pazopanib Hydrochloride is manufactured under strict Good Manufacturing Practice (GMP) guidelines to ensure high purity and consistency for clinical trials and commercial distribution. It is typically supplied as a white to off-white crystalline powder, suitable for tablet manufacturing. While generally well-tolerated, clinical use requires monitoring for potential adverse effects such as hypertension, liver toxicity, and gastrointestinal disturbances. As research continues into combination therapies and new indications, Pazopanib Hydrochloride remains a cornerstone agent in modern precision medicine, offering hope to patients with refractory malignancies. Its development marks a significant advancement in targeted cancer therapy, shifting the paradigm from cytotoxic chemotherapy to mechanism-based inhibition of tumor vasculature.